Effects of Metformin Monotherapy Versus Metformin Plus SGLT-2 Inhibitor Therapy on Molecular and Cellular Inflammatory Markers in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Bennur Esen, Damla Yildiz, Ahmet Engin Atay · 2026

Read Effects of Metformin Monotherapy Versus Metformin Plus SGLT-2 Inhibitor Therapy on Molecular and Cellular Inflammatory Markers in Patients with Newly Diagnosed Type 2 Diabetes Mellitus by Bennur Esen, Damla Yildiz, Ahmet Engin Atay (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13566505.txt.

Description

Bennur Esen, Damla Yildiz and Ahmet Engin Atay compared two starter treatments for newly diagnosed type 2 diabetes in 2026. Sixty-four patients took either metformin alone or metformin plus an SGLT-2 inhibitor for six months, with inflammation markers tracked alongside blood sugar control.

Both groups improved: TNF-alpha, IL-6, HbA1c and fasting glucose all fell. After adjusting for starting values, the combination group ended with significantly lower IL-6, and uric acid was also lower in an unadjusted comparison. Other markers, including C-reactive protein and combined inflammation indices, showed no clear group difference. The study suggests the added drug mainly deepens one strand of the anti-inflammatory effect.

Catalog record

CREATORBennur Esen, Damla Yildiz, Ahmet Engin Atay
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13566505

Browse the full library · About the Tower of Babel